Literature DB >> 31513751

Beyond the Lungs: Systemic Manifestations of Pulmonary Arterial Hypertension.

Nils P Nickel1, Ke Yuan1, Peter Dorfmuller2, Steeve Provencher3, Yen-Chun Lai4, Sebastien Bonnet3, Eric D Austin5, Carl D Koch6, Alison Morris6, Frédéric Perros3,7, David Montani7,8, Roham T Zamanian1, Vinicio A de Jesus Perez1.   

Abstract

Pulmonary arterial hypertension (PAH) is a disease characterized by progressive loss and remodeling of the pulmonary arteries, resulting in right heart failure and death. Until recently, PAH was seen as a disease restricted to the pulmonary circulation. However, there is growing evidence that patients with PAH also exhibit systemic vascular dysfunction, as evidenced by impaired brachial artery flow-mediated dilation, abnormal cerebral blood flow, skeletal myopathy, and intrinsic kidney disease. Although some of these anomalies are partially due to right ventricular insufficiency, recent data support a mechanistic link to the genetic and molecular events behind PAH pathogenesis. This review serves as an introduction to the major systemic findings in PAH and the evidence that supports a common mechanistic link with PAH pathophysiology. In addition, it discusses recent studies describing morphological changes in systemic vessels and the possible role of bronchopulmonary anastomoses in the development of plexogenic arteriopathy. On the basis of available evidence, we propose a paradigm in which metabolic abnormalities, genetic injury, and systemic vascular dysfunction contribute to systemic manifestations in PAH. This concept not only opens exciting research possibilities but also encourages clinicians to consider extrapulmonary manifestations in their management of patients with PAH.

Entities:  

Keywords:  cerebrovascular disease; coronary artery disease; kidney disease; pulmonary hypertension; respiratory muscle dysfunction

Mesh:

Year:  2020        PMID: 31513751      PMCID: PMC6961748          DOI: 10.1164/rccm.201903-0656CI

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  90 in total

1.  Sublingual microcirculation in pulmonary arterial hypertension.

Authors:  Luma Dababneh; Frank Cikach; Laith Alkukhun; Raed A Dweik; Adriano R Tonelli
Journal:  Ann Am Thorac Soc       Date:  2014-05

2.  The bronchial arteries in chronic obstructive pulmonary disease.

Authors:  S F Boushy; L B North; J A Trice
Journal:  Am J Med       Date:  1969-04       Impact factor: 4.965

3.  Association Between BMI and Obesity With Survival in Pulmonary Arterial Hypertension.

Authors:  Jason Weatherald; Alice Huertas; Athénaïs Boucly; Christophe Guignabert; Yu Taniguchi; Yochai Adir; Mitja Jevnikar; Laurent Savale; Xavier Jaïs; Mingkai Peng; Gérald Simonneau; David Montani; Marc Humbert; Olivier Sitbon
Journal:  Chest       Date:  2018-05-22       Impact factor: 9.410

4.  Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension.

Authors:  Derliz Mereles; Nicola Ehlken; Sandra Kreuscher; Stefanie Ghofrani; Marius M Hoeper; Michael Halank; F Joachim Meyer; Gabriele Karger; Jan Buss; Jana Juenger; Nicole Holzapfel; Christian Opitz; Jörg Winkler; Felix F J Herth; Heinrike Wilkens; Hugo A Katus; Horst Olschewski; Ekkehard Grünig
Journal:  Circulation       Date:  2006-09-18       Impact factor: 29.690

Review 5.  Pulmonary vascular remodeling in pulmonary hypertension.

Authors:  Rubin M Tuder
Journal:  Cell Tissue Res       Date:  2016-12-26       Impact factor: 5.249

6.  Dietary nitrite prevents hypercholesterolemic microvascular inflammation and reverses endothelial dysfunction.

Authors:  Karen Y Stokes; Tammy R Dugas; Yaoping Tang; Harsha Garg; Eric Guidry; Nathan S Bryan
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-02-27       Impact factor: 4.733

7.  Assessment of daily life physical activities in pulmonary arterial hypertension.

Authors:  Vincent Mainguy; Steeve Provencher; François Maltais; Simon Malenfant; Didier Saey
Journal:  PLoS One       Date:  2011-11-16       Impact factor: 3.240

8.  Risk factors for hemoptysis in idiopathic and hereditary pulmonary arterial hypertension.

Authors:  Darryl Tio; Edward Leter; Bart Boerrigter; Anco Boonstra; Anton Vonk-Noordegraaf; Harm Jan Bogaard
Journal:  PLoS One       Date:  2013-10-23       Impact factor: 3.240

Review 9.  The link between chronic kidney disease and cardiovascular disease.

Authors:  Sarmad Said; German T Hernandez
Journal:  J Nephropathol       Date:  2014-07-01

10.  Bilaterally dilated episcleral vessels in patients with heritable pulmonary arterial hypertension.

Authors:  Meri Watanabe; Shinji Makino; Hiroto Obata
Journal:  J Gen Fam Med       Date:  2017-06-01
View more
  16 in total

1.  Assessing the cancer hypothesis of pulmonary arterial hypertension: the devil is in the detail.

Authors:  Andrea L Frump; Yen-Chun Lai; Tim Lahm
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-03-18       Impact factor: 5.464

Review 2.  Hypoxia-inducible factor signaling in pulmonary hypertension.

Authors:  Soni Savai Pullamsetti; Argen Mamazhakypov; Norbert Weissmann; Werner Seeger; Rajkumar Savai
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808

3.  Update in Pulmonary Vascular Diseases and Right Ventricular Dysfunction 2019.

Authors:  Elena A Goncharova; Stephen Y Chan; Corey E Ventetuolo; Norbert Weissmann; Ralph T Schermuly; Christopher J Mullin; Mark T Gladwin
Journal:  Am J Respir Crit Care Med       Date:  2020-07-01       Impact factor: 21.405

4.  Abnormal Liver Function Tests Were Related to Short- and Long-Term Prognosis in Critically Ill Patients With Primary Pulmonary Hypertension.

Authors:  Dayu Wang; Suiqing Huang; Guangtao Xu; Sha Wu; Zhen Liu; Long Xu; Bo Hu; Jian Hou
Journal:  Front Cardiovasc Med       Date:  2022-06-02

Review 5.  Stem cell therapy for pulmonary arterial hypertension: An update.

Authors:  Qiwei Wilton Sun; Zhongjie Sun
Journal:  J Heart Lung Transplant       Date:  2022-03-06       Impact factor: 13.569

6.  Disease-specific platelet signaling defects in idiopathic pulmonary arterial hypertension.

Authors:  Kulwant S Aulak; Sami Al Abdi; Ling Li; Jack S Crabb; Arnab Ghosh; Belinda Willard; Dennis J Stuehr; John W Crabb; Raed A Dweik; Adriano R Tonelli
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-02-17       Impact factor: 5.464

7.  Mortality, Kidney Failure, and Hospitalization Among Medicare Beneficiaries With CKD and Pulmonary Hypertension.

Authors:  Sankar D Navaneethan; Carl P Walther; L Parker Gregg; Shweta Bansal; Wolfgang C Winkelmayer; Vijay Nambi; Jingbo Niu
Journal:  Am J Kidney Dis       Date:  2021-04-24       Impact factor: 8.860

8.  Brain Structural Changes in Patients with Pulmonary Arterial Hypertension.

Authors:  Bhaswati Roy; Susana Vacas; Luke Ehlert; Kathy McCloy; Rajan Saggar; Rajesh Kumar
Journal:  J Neuroimaging       Date:  2021-02-09       Impact factor: 2.486

Review 9.  Skeletal and Respiratory Muscle Dysfunctions in Pulmonary Arterial Hypertension.

Authors:  Marianne Riou; Mégane Pizzimenti; Irina Enache; Anne Charloux; Mathieu Canuet; Emmanuel Andres; Samy Talha; Alain Meyer; Bernard Geny
Journal:  J Clin Med       Date:  2020-02-03       Impact factor: 4.241

10.  Continuous reduction in cerebral oxygenation during endurance exercise in patients with pulmonary arterial hypertension.

Authors:  Simon Malenfant; Patrice Brassard; Myriam Paquette; Olivier Le Blanc; Audrey Chouinard; Sébastien Bonnet; Steeve Provencher
Journal:  Physiol Rep       Date:  2020-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.